BPC 157: Miracle Healing Peptide or Hidden Danger? FDA's Overreach on Compounded Peptides Is Your Peptide Store Website FDA Aligned? onPoint Studio Web Design and Development Services In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York